C.R. Bard Reveals Latest Litigation Cases in SEC Filing

Performance filings with the US Securities and Exchange Commission (SEC) are instructive in more ways than one, as documents often reveal the state of a corporation’s liability and litigation threats. Such is the case with C.R. Bard Inc. (C.R. Bard), a noted manufacturer of inferior vena cava filters that has been targeted with a rash of IVC Filter lawsuits.

To that end, the manufacturer of the Bard G2 IVC filter noted in its most current Form 10-Q Report for the period ending September 30th that it was facing 1,055 lawsuits in various federal and state jurisdictions.You can also contact Bard IVC Filter Attorneys for IVC Filter Complications Lawsuits.

Bard IVC filter lawsuits came under the scrutiny of the Judicial Panel for Multi-District Litigation in August of last year, which proceeded to move over 1,000 lawsuits into the Bard MDL. It has been reported that another 50 cases are currently pending in several state courts, with another 40 claims which thus far have been threatened with litigation, but as of the close of September had not yet been filed.

C.R. Bard is one of the several manufacturers dealing with allegations of defective products after scores of inferior vena cava filter patients have alleged injury after struts inherent to the design of the removable filters have broken free, and have migrated along the inferior vena cava artery to the heart and other organs.

The IVC filter itself has, in some cases, migrated away from the insert point and caused injury to the patient, or put the patient within imminent danger should the filter, or any of its part, reach the heart or lungs.

Allegations persist that C.R. Bard allowed for the allegedly tried Bard Recovery IVC filter to remain on the market for a period of years – without an IVC filter recall – before introducing its successor, the Bard G2 IVC filter.


Leave a Reply